Indivior PLC stock (GB00BYZ0C031): shares trade quietly as investors focus on valuation metrics

Indivior PLC shares on Nasdaq remain relatively steady while investors digest the latest quarterly figures and updated valuation metrics for the specialty addiction-treatment group based in the United Kingdom.

Indivior PLC shares traded at USD 15.45 on 06/05/2026 on Nasdaq under the ticker INDV, according to Morningstar as of 06/05/2026, keeping the United Kingdom-based addiction-treatment specialist in focus for investors watching the pharmaceuticals segment.

The company is headquartered in the United Kingdom and its primary listing is in its home market, but its U.S.-traded shares provide a key reference point for global investors tracking liquidity and valuation in USD terms.

As of: 05/06/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Indivior
• Sector/industry: Pharmaceuticals, addiction treatment
• Headquarters/country: Richmond, United Kingdom
• Core markets: United States, United Kingdom, global specialty pharma markets
• Key revenue drivers: Medications for opioid use disorder and related addiction therapies
• Home exchange/listing venue: London Stock Exchange (INDV); Nasdaq (INDV) as secondary listing
• Trading currency: GBP in London, USD on Nasdaq

Indivior PLC: core business model

Indivior focuses on developing and commercializing prescription therapies for opioid use disorder and related addiction conditions, with sales concentrated in markets where its flagship treatments for dependency management hold strong reimbursement and prescriber adoption.

Valuation metrics and multiples for Indivior PLC

With a Nasdaq quote of USD 15.45 as of 06/05/2026, according to Morningstar as of 06/05/2026, investors can benchmark Indivior PLC against other specialty pharmaceutical names on standard valuation ratios such as price-to-earnings and enterprise-value-based metrics, although detailed multiples depend on the latest reported earnings and balance-sheet data.

According to Indivior’s most recent quarterly report published on its investor relations site on 05/02/2026, the company reported continued revenue from its portfolio of opioid use disorder treatments for the period ended 03/31/2026, which underpins the earnings base used in current valuation frameworks on the London Stock Exchange and on Nasdaq.Indivior investor relations as of 05/02/2026

Conclusion

Indivior PLC’s Nasdaq-quoted shares at USD 15.45 as of early June 2026 provide a reference point for how the market currently values its addiction-treatment franchise relative to other specialty pharmaceutical names.

With the latest quarterly figures from 03/31/2026 now available to investors, the market has a recent earnings base for assessing valuation ratios and risk-reward profiles in both London and U.S. trading.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.